Seek Returns

ASND vs. REGN: Ascendis Pharma vs. Regeneron Pharmaceuticals Stock Comparison

How do Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
Profile ItemASNDREGN
NameAscendis Pharma A/SRegeneron Pharmaceuticals, Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization16.90 billion USD93.55 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 28, 2015April 2, 1991
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ASND
REGN
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Total Return (1Y)29.46%40.87%
Total Return (3Y, Annualized)40.62%5.15%
Total Return (5Y, Annualized)10.03%8.58%

Risk Profile

Drawdown History

ASND
REGN
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Volatility (1Y, Annualized)38.62%34.08%
Beta (5Y)0.380.10
Max Drawdown (5Y)-55.93%-59.69%
Avg. Volume (3M)698.39K772.95K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ASND and REGN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Sharpe Ratio (1Y)0.651.07
Sortino Ratio (1Y)0.991.70

Profitability

ROE (TTM)

Both companies show strong equity returns, but Ascendis Pharma (ASND) at 118.78% is the standout with ROE above its industry range; Regeneron Pharmaceuticals (REGN) at 14.95% also sits in the top quartile.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

118.78%

ASND
118.78%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max
109.18%
REGN
14.95%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Ascendis Pharma (ASND) at 70.85% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

70.85%

ASND
70.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN
28.51%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Ascendis Pharma (ASND) at 64.98% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

64.98%

Max
83.12%
ASND
64.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max
83.12%
REGN
40.46%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
ROE (TTM)118.78%14.95%
ROA (TTM)9.58%7.59%
Net Margin (TTM)70.85%28.51%
Operating Margin (TTM)64.98%40.46%
Gross Margin (TTM)91.30%46.73%

Growth

Revenue Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Regeneron Pharmaceuticals (REGN) at 0.99% is closer to the peer norm — faster top-line expansion for ASND.

Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Revenue Growth (YoY)98.03%0.99%
Revenue Growth (3Y CAGR)141.43%5.62%
EPS Growth (YoY)--8.19%
EPS Growth (3Y CAGR)--2.77%

Financial Strength

Current Ratio (MRQ)

Both Ascendis Pharma (ASND) at 2.99 and Regeneron Pharmaceuticals (REGN) at 3.35 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max
25.13
Q3
12.13
Median
5.52
ASND
2.99
Q1
2.47
Min
0.10

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max
25.13
Q3
12.13
Median
5.52
REGN
3.35
Q1
2.47
Min
0.10
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Ascendis Pharma (ASND) at 0.31 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
ASND
0.31
Median
0.15
Q1
0.02
Min
0.00

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max
1.42
Q3
0.65
Median
0.15
REGN
0.08
Q1
0.02
Min
0.00
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Current Ratio (MRQ)2.993.35
Debt / Equity (MRQ)0.310.08
Net Debt / EBITDA-1.37-1.17

Dividends

Dividend Yield (TTM)

Ascendis Pharma (ASND) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN
0.41%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Ascendis Pharma (ASND) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN
8.18%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
Dividend Yield (TTM)0.00%0.41%
Dividend Payout Ratio (TTM)0.00%8.18%

Valuation

P/E Ratio (TTM)

Both Ascendis Pharma (ASND) at 19.68 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.68

Max
85.34
Q3
43.46
Median
26.69
ASND
19.68
Q1
13.30
Min
0.07

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max
85.34
Q3
43.46
Median
26.69
REGN
19.99
Q1
13.30
Min
0.07
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.14

Max
58.18
Q3
25.77
ASND
16.14
Median
7.30
Q1
3.01
Min
0.01

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max
58.18
Q3
25.77
Median
7.30
REGN
5.54
Q1
3.01
Min
0.01
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.45

Max
13.53
ASND
10.45
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max
13.53
Q3
6.54
Median
3.25
REGN
2.71
Q1
1.69
Min
-5.59
Loading chart…
Ascendis Pharma (ASND) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Ascendis Pharma (ASND) and Regeneron Pharmaceuticals (REGN)
MetricASNDREGN
P/E Ratio (TTM)19.6819.99
P/S Ratio (TTM)16.145.54
P/B Ratio (MRQ)10.452.71
Free Cash Flow Yield (TTM)0.08%2.76%